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some unstable species including small mammals and birds. A fundamental 
assumption in many of our studies is that that the heavily infected individuals 
are. responsible for much of the transmission but we have preliminary 
.evidence that this may not be the case and other factors including secondary 
'infections and host status influence the likelihood of being a shedder and a 
spreader. 
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Tasmanian Devil Facial Tumour Disease: a parasitic clonally-
reproducing mammal, which threatens to cause extinction of an iconic 
"species 
::Hamish McCallum 
~University of Tasmania, Australia 
tasmanian Devil facial tumour disease is an infectious cancer. The tumour 
cells themselves are the infectious agent, tumours are genetically distinct from 
their hosts and all tumours are derived from one, long dead individual. The 
tumour cell line is a parasitic, c1onally-reproducing mammal. The tumour, 
which emerged in the mid-1990s, is transmitted by biting and continues to 
spread across the range of the devil, causing an overall population decline of 
50% (up to 90% in affected areas). Models and current population trends 
project extinction within 25-30 years, with no disease-free populations 
remaining within five years. We estimated the rate of disease transmission in 
natural populations. Prevalence did not differ between male and female devils, 
although there were strong age-class effects. The rate of increase in 
prevalence differed between three sites monitored from the time of disease 
arrival, but was not related to host density. Prevalence remained high despite 
major decreases in devil density, suggesting little association between host 
density and transmission. Estimates of transmission rates suggest it may be 
possible to suppress disease by removing at least 50% of diseased animals 
eVf;ry three months. A trial on a semi-isolated peninsula provides evidence 
'ihat this strategy might be successful. 
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Parasitic nematodes, particularly the pig whipworm, Trichuris suis, and the 
human hookworm, Necator americanus, are being used to treat human 
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autoimmune disease. Currently, these "treatments" are only available through 
research projects or as unregistered treatments. Eggs of whipworms for the 
;treatment of inflammatory bowel disease were previously available 
commercially in USA with FDA approval, but not now. 
What is the evidence for the hypothesis that intestinal helminths can improve 
clinical outcomes in autoimmune disease? The initial stimulus was that 
'epidemiological data indicated an inverse association between the prevalence 
;bf intestinal helminths and the prevalence of inflammatory bowel disease, 
asthma, allergic rhinitis and multiple sclerosis between countries and also 
'Within countries over time. The next step was prospective studies that 
;~emonstrated treating helminths in endemic countries rapidly increased the 
Tncidence of allergic responses. One serendipitous case study showed that 
'treatment of enterobiasis caused loss of colonic wall T-reg cells and was 
followed by the development of ulcerative colitis. 
Trials on use of T. suis and N. americanus in humans with inflammatory bowel 
disease and allergic rhinitis marked the next intervention phase. Current 
-research now seeks to understand host-parasite mechanisms and to isolate 
active compounds to bypass the use of live parasites. 
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If you can't solubilise, you can't analyse. This simple statement presents a 
major challenge on two levels, firstly the chemical diversity within even the 
simplest proteome cannot be captured by any single extraction and separation 
,step, and consequently, the wealth of literature on sample preparation is 
equally diverse. Secondly, a relatively small number of proteins are present in 
high concentration, whilst the majority are expressed at less than 50,000 
copies per cell. This dynamic range issue, coupled with the chemical diversity 
b:as made sample preparation and fractionation key technology development 
areas of proteomics. In this presentation I will briefly focus on two of the 
sample preparation and fractionation techniques used in our lab. 
1. Enriching low abundance proteins by proteome-wide affinity using a 
combinatorial hexapeptide library. We have worked with derivatisation of 
proteins to enable a wider range of insoluble or hydrophobic proteins to be 
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